anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention is directed to a target-derived neuronal cholinergic differenciation factor (NCDF), and the therapeutic and diagnostic uses thereof. The invention provides NCDF, and derivatives, analogs, and fragments thereof, pharmaceutical compositions containing the foregoing, as well as anti-NCDF antibodies. The NCDF of the invention is a protein present in extracts of mammalian sweat glands, which exhibits heat and trypsin lability, lack of substantial binding to a heparin-agarose affinity column, an isoelectric point (pI) in the range of approximately 4.8 to 5.2, a non-membrane cellular localization, and an approximate molecular weight in the range of 16 to 32 kilodaltons. The NCDF protein, its derivatives, analogs, and fragments are able to reduce the expression of tyrosine hydroxylase and of total catecholamines, and increase the expression of choline acetyltransferase and vasoactive intestinal peptide (VIP), by sympathetic neurons in cell culture. The NCDF protein, its derivatives, analogs, and fragments, can be used to induce cholinergic activity in neurons. Such proteins, derivatives, analogs and fragments can be administered therapeutically to patients with nervous system damage or diseases where it is desirable to support survival and/or cholinergic differentiation of a number of neuronal types.
Subjects will be recruited up to the day of surgery. 90 subjects will be randomly allocated into 2 groups, using a computer generated table of random numbers: anesthetic maintenance with Sevoflurane or anesthetic maintenance with Propofol . Subjects will be premedicated with intravenous (IV) midazolam 0.04 mg/kg. Routine ASA monitors will be applied. Anesthesia will be induced with remifentanil infusion started at 0.1 mcg/kg/minute titrated to keep blood pressure within 20% of the baseline and propofol 1.0 -2.0 mg/kg or sevoflurane induction. Tracheal intubation will be facilitated with rocuronium (0.6 mg/kg) or succinylcholine (1-2mg /kg). Anesthesia will be maintained with Sevoflurane or a Propofol infusion titrated to keep a bispectral index between 40-60, remifentanil infusion started at 0.1mcg/kg/min titrated to keep blood pressure within 20 % of baseline values, and rocuronium that will be administered at the discretion of the anesthesiologist. Upon termination of the surgery, neuromuscular blockade will be antagonized with a combination of neostigmine 0.05mg/kg and glycopyrrolate 0.01 mg/kg. Subjects will also receive Ketorolac 30 mg IV after discontinuation of remifentanil for postoperative pain control. Ondansetron 4 mg IV will be administered to decrease postoperative nausea and vomiting. Subjects will receive IV hydromorphone 0.4 mg q 5 minutes as needed to achieve a verbal rating score for pain \<4 out of 10.They will also receive reglan 10 mg IV as a rescue antiemetic, if not effective, a second dose of Zofran 4 mg IV will be given in PACU. 24 hours after surgery a QOR 40 will be administered to the patient by one of the investigators. The primary and secondary outcomes will be assessed by an independent observer who will be blinded to group allocation.
The invention relates to a natural plant formula for hair blacking and white hair delaying. The natural plant formula is prepared from the following raw materials: radix polygonum multiflorum preparata, semen sesami nigrum, mulberry, angelica sinensis, cacumen biotae, herba ecliptae, platycladi seed, mint, scutellaria baicalensis, semen cuscutae, radix angelicae pubescentis, seaweed, salvia miltiorrhiza, glossy privet fruit, stir-fried fructus viticis, fructus lycii, radix astragali, rhizoma smilacis glabrae and ginseng. The invention also provides a preparation method and application of the natural plant formula. The natural plant formula has the following advantages: the natural plant formula is safe and does not cause bad irritation to skin according to skin irritation experiments; and according to skin acute toxicity tests, the natural plant formula does not cause acute toxic reaction. The natural plant formula provided by the invention is proved by animal experiments and human experiments to be effective in hair blacking and white hair delaying. According to the study on the in-vivo action mechanism, the natural plant formula provided by the invention can effectively activate tyrosinase so as to promote melanogenesis and improve related diseases.
Stimulation of the angiotensin II type 1 (AT1) receptors after arterial injury promotes vascular smooth muscle cell (VSMC) migration, proliferation, and extracellular matrix production, leading to the hope that blockade of this receptor by angiotensin-converting enzyme inhibitors (ACEI) or specific (AT1) receptor antagonists (ARBs) might reduce intimal hyperplasia. However, despite confirmatory evidence in several animal models of restenosis, the large scale MERCATOR and MARCATOR trials of cilazapril with balloon angioplasty failed to show benefit. In 1999, Kondo reported the results of a randomized pilot trial of 100 patients who received Palmaz-Schatz stents and were randomized to receive the ACE inhibitor quinapril or placebo. The volume of neointimal hyperplasia assessed by IVUS was significantly less quinapril than the control group (18 ± 0.6 mm3 vs. 25 ± 0.6 mm3; p \< 0.05). The quinapril group's restenosis rate was 16%, with the quinapril benefit being observed only in patients with the D/D and I/D genotypes. Also, other study reported on a consecutively treated cohort of 1,598 stented patients, noting that ACE inhibitor usage at the time and after stenting reduced the risk of subsequent revascularization dramatically (adjusted odds ratio, 0.46; p = 0.001). In the ValPREST trial which is a single-center randomized trial of patients receiving stents for type B2/C lesions, comparing valsartan (and ARV) 80 mgs daily with open treatment, patients randomized to valsartan had a 19% incidence of restenosis compared with 39% in the open treatment arm (p = 0.005).

Recently, several randomized studies were conducted to compare the safety and efficacy of the two leading drug-eluting stent (DES). However, data on the association of ARBs for suppression of neointimal hyperplasia are limited in the DES era. Therefore, a pivotal randomized study is warranted.
Patients receive nivolumab IV over 30 minutes on day 1 and cabozantinib S-malate PO daily. Cycles repeat every 4 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood at baseline and on study, CT scan, spiral CT, or MRI, or FDG-PET scan throughout the trial.
Diabetic cardiomyopathy (dCM) is a major complication of diabetes; however, specific treatments for dCM are currently lacking. RTA 408, a semisynthetic triterpenoid, has shown therapeutic potential against various diseases by activating the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway. We established in vitro and in vivo models using high glucose toxicity and db/db mice, respectively, to simulate dCM. Our results demonstrated that RTA 408 activated Nrf2 and alleviated various dCM-related cardiac dysfunctions, both in vivo and in vitro. Additionally, it was found that silencing the Nrf2 gene eliminated the cardioprotective effect of RTA 408. RTA 408 ameliorated oxidative stress in dCM mice and high glucose-exposed H9C2 cells by activating Nrf2, inhibiting mitochondrial fission, exerting anti-inflammatory effects through the Nrf2/NF-κB axis, and ultimately suppressing apoptosis, thereby providing cardiac protection against dCM. These findings provide valuable insights for potential dCM treatments.NEW & NOTEWORTHY We demonstrated first that the nuclear factor erythroid 2-related factor 2 (Nrf2) activator RTA 408 has a protective effect against diabetic cardiomyopathy. We found that RTA 408 could stimulate the nuclear entry of Nrf2 protein, regulate the mitochondrial fission-fusion balance, and redistribute p65, which significantly alleviated the oxidative stress level in cardiomyocytes, thereby reducing apoptosis and inflammation, and protecting the systolic and diastolic functions of the heart.
The present invention discloses medicine for treating arthritis pain and a preparation method thereof. Traditional Chinese medicine which mainly comprises starflowerlike loosestrife root or herb, summer eupatorium fortunei, common monkshood mother root, kusnezoff monkshood root, frankincense, myrrh, realgar, RHIZOMA ARISAEMATIS, manchurian wildginger, tall gastrodis tuber, etc., is selected to combine with seedling medicine. The medicine is combined, which enables each medicine efficacy to generate synergistic effect. Thus, arthralgia is effectively treated. The present invention can dispel cold, remove dampness, promote blood circulation for removing obstruction in collaterals, reduce edema and alleviate pain. The present invention is external application medicine having the advantages of good treating efficacy, high efficiency, no toxic side effect and no stimulation to skins.
Using a fracture table, the affected leg will be placed into traction and the patient will be prepped and draped in the usual fashion. The fracture will be provisionally reduced using closed techniques. A 3cm incision will be used to gain access to the intramedullary canal and the nail (either a short nail or long nail, at the discretion of the treating surgeon) will be introduced to the femur. The screw will be placed across the fracture and into the femoral head, aiming for a tip-to-apex distance of less than 25mm. The compression nut will be used to compress the fracture. The screw will then be statically locked using the 6Nm torque-limiting blue handle with 6mm hex coupling to completely lock the set screw down on the helical screw.
The novel class of the biodegradable pharmaceutical compositions used as the controlled release dosage forms is described. The methods for manufacturing and administering these compositions are disclosed. The process of their manufacture comprises: a) dry mixing of the pharmaceutically active substance with the biodegradable polymer; b) the extrusion of the melted mixture producing the solid solution of the active substance in the polymer; c) grinding of the solid solution producing the microparticles acceptable for the injection dosage forms. Preferably, these compositions comprise copolymer of lactide-glycolide and (+)- -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol as an active ingredient. The specified compositions release an active ingredient at a constant rate for a period from several days to several weeks. The active ingredient is the antagonist of 5HT2A-receptor. The specified compositions may be used for treating psychosis, including schizophrenia, the compulsive disorders, the disorders of sleep, the depression, the anorexia, the anxious states, the drug addiction, and the bipolar disorders.
Participants attend an audio-taped focus group over 1 hour and are given the APPSPIRE app. After 1 and 4 months of using the app, participants complete a telephone survey over 1 hour to discuss how they liked the app and its usefulness.
Worldwide most of the people belong to all age group may affected with Non communicable diseases(NCD) which leads them toward death globally . According to stats World Health Organization (WHO) declares about 41 million people are died due to NCD which means about 71 %people are died globally due to this .Chronic Respiratory diseases are one of the main non communicable disease . About 9.0 million(3.6%) adult belong to age group of 18 or older may suffer from chronic bronchitis . Hallmark of chronic bronchitis is that cough and sputum production for more than \>3months in each of at least two connective years. Chronic bronchitis effects every third person having COPD but it may effect any body who had normal pulmonary functions. Now a days positive expiratory pressure (PEP)devices are used along Cardio Pulmonary Therapy(CPT) .PEP devices are help full in mobilize the secretion in lower respiratory tract , may also beneficial in collateral ventilation ,mucous secretion and most importantly optimize functional residual capacity among people who had pulmonary complications. Many PEP devices are available in market but BBPEP is in low cost and are easily in approach of every single person .PEP is non invasive technique used to improve clinical outcome .

In this study investigator compare the effect of BBPEP and Acapella in participant having chronic bronchitis .In case of BBPEP patient expires against resistance of water column which increase PEP ( positive expiratory pressure ) in inlet which transferred airway patients lungs this will keep the alveoli patent or may recruit the collapsed alveoli. This will decrease airway resistance and improve lung compliance . As airway resistance decreases the amount of SPO2 AND PEFR also improved . participant are randomly assigned into two different group GROUP(A) AND GROUP(B) Group (A) receive intervention by using BBPEP device along with deep breathing exercises group (B)participant use acapella devices so out come will be measured participant rotate the device toward positive(+) sign to increase resistance or may rotate device to minus (-) to decrease resistance participant is in comfortable short sitting position ask him to take deep breath and hold it for 3 sec nose clip attached to the participant participant lips sealed mouthpiece ask him to exhale into mouth piece maneuver repeated for 10 to 12 breath with 3 to 4 huffs all the steps repeated for 15 minute. study will be carried out for 8 weeks , 3 days per week. Outcome variables will be Peak flow meter , pulse oximeter ,casa q scale ,heart rate, respiratory rate blood pressure. Data will be analyzed on SPSS-25.
DIRECTIONS FOR USE: {Best Results • Use Early Morning)

1\. Each pupil receives one cup and one napkin. 2. Have the pupils remove the lids from the cups. 3. Have the pupils empty the contents of the cup into their mouths and swish thoroughly for one minute. 4. HOLD CUP AGAINST THE MOUTH. Spit solution back into the cup. 5. Have the pupils wipe their mouths with the napkin; then stuff the napkin slowly into the cup to absorb the solution. 6. Discard the cup with the napkin into the provided trash bag. a) Do not swallow b) Do not eat, drink or rinse with water for 30 minutes after use. c) Instruct children under 12 years of age in the use of the product and in good brushing and rinsing habits to minimize swallowing d) Not recommended for use in children younger than 6 years of age. ADDITIONAL INSTRUCTIONS/IMPORTANT: In order to avoid spillage of the solution from the cup, the children must be instructed to do the following: 1) When spitting the fluoride solution from the mouth back into the cup, the children must hold the cup close to the mouth, and spit slowly into the cup. 2) The napkins must be stuffed into the cups very slowly in order to avoid spillage.
PURPOSE:To obtain the titled composite having excellent accumulation tendency to cancer cell and high storage stability, in high yield, by reacting a carcinostatic substance and a carrier to a dextran containing an aldohexopyranose ring cleaved by a specific treatment. CONSTITUTION:The objective composite composed of a carcinostatic substance, a dextran containing cleaved aldohexopyranose ring and a carrier is produced by protecting 5-70%, preferably 10-40% of the aldehyde group of a dextran containing cleaved aldohexopyranose ring (having a molecular weight of preferably, 1,000-2,000,000) and reacting (A) the protected dextran with (B) a carcinostatic substance (e.g. adriamycin, daunomycin, etc.) and (C) a carrier (e.g. gamma-globulin, monoclonal antibody for cancer, fibronectin, transferrin, fibrinogen, etc.). The protection of the aldehyde group is usually carried out by the reaction of a compound having amino group (e.g. amino acid).
Empirical evidence suggests fishes meet the criteria for experiencing pain beyond a reasonable doubt and zebrafish are being increasingly used in studies of pain and nociception. Zebrafish are adopted across a wide range of experimental fields and their use is growing particularly in biomedical studies. Many laboratory procedures in zebrafish involve tissue damage and this may give rise to pain. Therefore, this FELASA Working Group reviewed the evidence for pain in zebrafish, the indicators used to assess pain and the impact of a range of drugs with pain-relieving properties. We report that there are several behavioural indicators that can be used to determine pain, including reduced activity, space use and distance travelled. Pain-relieving drugs prevent these responses, and we highlight the dose and administration route. To minimise or avoid pain, several refinements are suggested for common laboratory procedures. Finally, practical suggestions are made for the management and alleviation of pain in laboratory zebrafish, including recommendations for analgesia. Pain management is an important refinement in experimental animal use and so our report has the potential to improve zebrafish welfare during and after invasive procedures in laboratories across the globe.
FIELD: medicine.SUBSTANCE: invention refers to experimental medicine and can be used for treating a bone defect experimentally. That is ensured by placing a resorbable synthetic membrane in the form of a film on a bone defect. Film base is a composition of polyvinyl alcohols of different saponification degree with addition of fullerenes Cin following ratio, wt%: unwashed polyvinyl alcohol – 38.9–39.1; polyvinyl alcohol of deep saponification degree 57.9–58.1; vinylamine – 2.9–3.1; fullerenes C– 0.02–0.001. Perforated holes are made along the entire surface of the film. Before film application on bone defect on its surface in contact with bone defect is applied gel based on composition of polyvinyl alcohols of different degree of saponification with addition of fullerenes Cin following ratio, wt%: sub-saponified polyvinyl alcohol – 4.9–5.1; polyvinyl alcohol of deep saponification degree 9.9–10.1; vinylin – 2.9–3.1; fullerenes C– 0.02–0.001; distilled water – balance. After the film is applied on the bone defect on the gel, which protrudes from the perforated holes in the film, and along its edges, a thickener is applied to produce a plasticine mass of the gel. Thickener is represented by powdered 100 % sub-saponified polyvinyl alcohol. Method provides higher efficiency of vascular tissue germination, which improves quality of bone regenerate maturation. This is achieved by the fact that the base of the resorbable synthetic membrane made in form of a film is a composition of polyvinyl alcohols of different degree of saponification with addition of fullerenes C. Before film application on bone defect on its surface in contact with bone defect is applied gel based on composition of polyvinyl alcohols of different degree of saponification with addition of fullerenes C. Perforated holes are made on the entire surface of the above film, and after its application on the bone defect on the gel, protruding from the perforated holes in the above film, and a thickener is applied along its edges to form a plasticine mass of the gel, wherein the thickener is powdered 100 % sub-saponified polyvinyl alcohol.EFFECT: method provides higher quality of maturation of bone regenerate due to higher efficiency of membrane fixation to bone edges of defect and efficiency of vascular tissue germination in the second stage of reparative osteogenesis.1 cl, 1 tbl, 1 ex
FIELD: veterinary. SUBSTANCE: this method prescribes intra-articularly administering bone marrow preparation produced from osteal cavity of metatarsal bones sawn crosswise in metaphysis after pasteurization and sterilization in water bath during 15 to 30 minutes at temperature of 70 to 80 C into animals suffering from arthrosis. Medicine should be administered in amount of 1.0 to 1.5 ml per 100 kg of live mass. Disclosed method further prescribes additionally administering 20-percent solution of camphoric oil in same dosage in case of grave case (III-rd stage of arthrosis). Recovery is expected on 21 - 21 day. EFFECT: higher effectiveness.
Sepsis is a life-threatening organ dysfunction triggered by an unregulated response of a host to infection. Sepsis is a reason for substantial mortality and morbidity among intensive care unit (ICU) patients. 1 The pathophysiology of sepsis has changed spectacularly over the last several decades. Significant comprehension into the components of the inflammatory response has been achieved. Inflammation contributes to endothelial injury and initiates coagulation pathways.2 The inflammatory reaction is mediated by the release of cytokines (tumor necrosis factor-alpha, interleukins, and prostaglandins) from neutrophils and macrophages. The cytokines trigger the extrinsic coagulation cascade and inhibit fibrinolysis. These overlapping processes end with organ dysfunction.3 The Sequential Organ Failure Assessment or SOFA score was developed to assess the acute morbidity of critical illness at a population level and has been extensively validated as a tool for this purpose across a range of healthcare settings and environments.4 Metformin is oral anti-diabetic agent that has positive effects such as antioxidant and anti-inflammatory properties which are considered potentially beneficial properties for management of septic patients. Previous studies showed that preadmission metformin use may reduce mortality in adult patients with sepsis and diabetes mellitus. Therefore, our study aims to test the potential efficacy of metformin in all subsets of patient with sepsis.5,6 Lactoferrin is a cationic glycoprotein and associated with many activities including the relevant anti-inflammatory one, especially associated to the downregulation of pro-inflammatory cytokines besides its anti-microbial and immunomodulatory effect.7 A previous study suggested that lactoferrin supplementation to enteral feeds with or without probiotics decreases late-onset sepsis in preterm infants without adverse effects and this encourage us to test its role in adult patients with sepsis.8 Therefore, the aim of our study is to compare the safety and efficacy of metformin and lactoferrin in ICU patients with sepsis.
PROBLEM TO BE SOLVED: To obtain an isatoic anhydride in a good yield in the improved volumetric efficiency of a reactor in a state inhibited in the whipped cream formation of the reaction mixture by reacting the corresponding anthranilic acid or its salt with phosgene in the presence of an alkylpyridinium salt. SOLUTION: (D) An anthranilic acid of formula II [R1 , R2 are each independently H, a halogen, nitro, an acyloxy, etc.; R3 is H, a halogen, nitro, a (halogenated) lower alkyl, etc.], or its salt is reacted with (C) phosgene in the presence of (A) an alkylpyridinium salt, preferably a compound of formula I (R6 is a 8-20C alkyl; R7 is H, a lower alkyl; X is an anion), in (B) an aqueous solvent to obtain (E) the objective isatoic acid anhydride of formula III. An organic solvent substantially immiscible with water and inactive to the reaction is preferably further added to the reaction system. The reaction is preferably carried out at a temperature of 0-40 deg.C in a component D/component C molar ratio of 1/(0.9-2) at a pH of 2-10 and subsequently at a pH of <2.
A method for communicating information related to a diagnostic analyzer includes receiving user identification information from a portable computer. A user associated with the user identification information operates the diagnostic analyzer. First diagnostic analyzer information is retrieved from at least one database that relates analyzer information to the user of the diagnostic analyzer. The first diagnostic analyzer information is related to the diagnostic analyzer. The first diagnostic analyzer information is communicated to the portable computer. Second diagnostic analyzer information from the diagnostic analyzer is retrieved. The second diagnostic analyzer information is generated by the diagnostic analyzer. The first and the second diagnostic analyzer information is communicated to the portable computer. The portable computer is configured to display the first and the second diagnostic analyzer related information.